Author + information
Damman P, Beijk MAM, Kuijt WJ, et al. Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2011;57:29–36.
In this paper, the following corrections are needed:
On page 29, in the first page abstract, in the last line of the Results section, the value for the net reclassification index should be changed from “(0.494, p < 0.001)” to “(0.481, p < 0.001)” and the integrated discrimination improvement should be changed from “(0.0295, p < 0.01)” to “(0.0226, p = 0.03).”
On page 31, in the right column, Results section, line 9, the sentence “There were clinically small, but statistically significant, differences in hypercholesterolemia, history of coronary artery bypass grafting, and prevalence of anterior MI” should be changed to “There were clinically small, but statistically significant, differences in hypercholesterolemia, history of coronary artery bypass grafting, time to treatment, and prevalence of anterior MI.”
On page 32, in Table 1, under “Laboratory assessments,” the “Time to treatment” values should be “190 (133–273)” in the study group and “161 (124–251)” in excluded patients, and the p value should be changed to “0.02.”
On page 33, in the left column, 2nd line from the bottom, the text should be changed from “intermediate-risk (17.4%)” to “intermediate-risk 20.3%.”
On page 33, in the right column, the section “Biomarkers and established risk factors” should be changed to read as follows:
Biomarkers and established prognostic factors
After adjustment for established risk factors, eGFR and NT-proBNP remained significant predictors for mortality, while a trend toward higher mortality was observed with higher glucose values (Table 3). An eGFR <60 ml/min was associated with a 3.57 increased mortality hazard (HR: 3.57, 95% CI: 1.57–8.11, p < 0.01). A glucose level ≥10 mmol/l (HR: 1.48, 95% CI: 0.83–2.64, p = 0.19) was associated with a trend toward higher mortality at the end of follow-up. Finally, a 2-fold increase in mortality was observed with NT-proBNP values ≥600 ng/l (p < 0.01). Adding eGFR, NT-proBNP, and glucose to the established risk factors improved the prediction of mortality, as shown by the increase in the Harrell's C index (Table 5). Reclassification of patients who died or were alive at follow up is presented by the NRI. Addition of each single biomarker (except glucose) or the 3 markers from our score significantly improved the reclassification of patients (p < 0.001). The integrated discrimination significantly improved after addition of NT-proBNP, eGFR, or the 3 markers.
Because we hypothesized that the relationship between admission glucose levels and mortality differed between diabetic and nondiabetic patients, we assessed the interaction between glucose and diabetes by testing the significance of this relation in the Cox proportional-hazards model with established risk factors. No interaction was observed (p = 0.85).
On page 35, in the right column, in the Study limitations section:
• In the 7th line from the top, the number of excluded patients should be changed from “279” to “249.”
• In the 9th line from the top, the following sentence should be deleted: “However, there were no statistically significant differences between included and excluded patients with the exception of more prior coronary artery bypass grafting procedures in the excluded patients.”
The authors apologize for these errors.
- American College of Cardiology Foundation